Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet

Current Medical Research and Opinion

Volumn 19, Issue 7, 2003, Pages 609-613

  Asnani, Sunil ^a   Richard, Byron C ^a   Desouza, Cyrus ^a   Fonseca, Vivian ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Low calorie diets; Obesity; Thiazolidinediones; Type 2 Diabetes Mellitus; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLIPIZIDE; HEMOGLOBIN A1C; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; PROPRANOLOL; QUINAPRIL; ROSIGLITAZONE;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BODY WEIGHT; CALORIC INTAKE; DIABETES MELLITUS; DIETARY INTAKE; FEMALE; HUMAN; HYPERTENSION; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; BEHAVIOR THERAPY; BODY WEIGHT; DIET, REDUCING; ENERGY INTAKE; EXTRACELLULAR FLUID; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; UNITED STATES; WEIGHT LOSS;

EID: 0142090761     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002306     Document Type: Article

References (24)

1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23(9):1278-83
2. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134(1):61-71
3. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog in Hormone Res 2001;56:265-94
4. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50(8):1863-71
5. Greenway MD. Obesity medications and treatment of type 2 diabetes. Diabetes Technol Ther 1999;1(3):277-87
6. Finer N. Low-calorie diets and sustained weight loss. Obes Res 2001;9(Suppl 4):290-4S
7. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135:798-800
8. Pelton PD, Zhou L, Demarest KT, Burris TP. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 1999;261(2):456-8
9. Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K, Fleckner J. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes 2002;51(4):1042-51
10. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor [gamma] have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53
11. Nakamura T, Funahashi T, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001;54(3):181-90
12. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23(8):1067-71
13. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74(4):761-811
14. 3 cotransport activity in rabbit proximal straight tubules. Exp Nephrol 2001;9(3):191-7
15. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272(6 Pt 1):E986-96
16. Hosokawa M, Tsukada H, Fukuda K, Oya M, Onomura M, Nakamura H, Kodama M, Yamada Y, Seino Y. Troglitazone inhibits bicarbonate secretion in rat and human duodenum. J Pharmacol Exp Ther 1999;290(3):1080-4
17. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998;47(5):810-14
18. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001;50(5):1166-70
19. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 2000;47(4):1147-57
20. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, Isner JM. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000;132(11):880-4
21. Williams KV, Mullen ML, Kelley DE, Wing RR. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care 1998;21(1):2-8
22. Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001;9(Suppl 4):348-53S
23. Bastard JP, Hainque B, Dusserre E, et al. Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low-calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev 1999;15(2):92-8
24. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99(10):2416-22